BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 22347510)

  • 1. Lithium treatment of APPSwDI/NOS2-/- mice leads to reduced hyperphosphorylated tau, increased amyloid deposition and altered inflammatory phenotype.
    Sudduth TL; Wilson JG; Everhart A; Colton CA; Wilcock DM
    PLoS One; 2012; 7(2):e31993. PubMed ID: 22347510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amyloid reduction by amyloid-beta vaccination also reduces mouse tau pathology and protects from neuron loss in two mouse models of Alzheimer's disease.
    Wilcock DM; Gharkholonarehe N; Van Nostrand WE; Davis J; Vitek MP; Colton CA
    J Neurosci; 2009 Jun; 29(25):7957-65. PubMed ID: 19553436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progression of amyloid pathology to Alzheimer's disease pathology in an amyloid precursor protein transgenic mouse model by removal of nitric oxide synthase 2.
    Wilcock DM; Lewis MR; Van Nostrand WE; Davis J; Previti ML; Gharkholonarehe N; Vitek MP; Colton CA
    J Neurosci; 2008 Feb; 28(7):1537-45. PubMed ID: 18272675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Xanthoceraside rescues learning and memory deficits through attenuating beta-amyloid deposition and tau hyperphosphorylation in APP mice.
    Jin G; Wang LH; Ji XF; Chi TY; Qi Y; Jiao Q; Xu Q; Zhou XY; Zhang R; Zou LB
    Neurosci Lett; 2014 Jun; 573():58-63. PubMed ID: 24810883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation.
    Rockenstein E; Torrance M; Adame A; Mante M; Bar-on P; Rose JB; Crews L; Masliah E
    J Neurosci; 2007 Feb; 27(8):1981-91. PubMed ID: 17314294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies.
    Nakashima H; Ishihara T; Suguimoto P; Yokota O; Oshima E; Kugo A; Terada S; Hamamura T; Trojanowski JQ; Lee VM; Kuroda S
    Acta Neuropathol; 2005 Dec; 110(6):547-56. PubMed ID: 16228182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tau passive immunization inhibits not only tau but also Aβ pathology.
    Dai CL; Tung YC; Liu F; Gong CX; Iqbal K
    Alzheimers Res Ther; 2017 Jan; 9(1):1. PubMed ID: 28073379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GRK5 dysfunction accelerates tau hyperphosphorylation in APP (swe) mice through impaired cholinergic activity.
    Zhang Y; Chen L; Shen G; Zhao Q; Shangguan L; He M
    Neuroreport; 2014 May; 25(7):542-7. PubMed ID: 24598771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fuzhisan ameliorates Aβ production and tau phosphorylation in hippocampal of 11month old APP/PS1 transgenic mice: A Western blot study.
    Zhang ZX; Zhao RP; Wang DS; Wang AN
    Exp Gerontol; 2016 Nov; 84():88-95. PubMed ID: 27612601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel GSK-3beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo.
    Serenó L; Coma M; Rodríguez M; Sánchez-Ferrer P; Sánchez MB; Gich I; Agulló JM; Pérez M; Avila J; Guardia-Laguarta C; Clarimón J; Lleó A; Gómez-Isla T
    Neurobiol Dis; 2009 Sep; 35(3):359-67. PubMed ID: 19523516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurotrophin receptor p75 mediates amyloid β-induced tau pathology.
    Shen LL; Li WW; Xu YL; Gao SH; Xu MY; Bu XL; Liu YH; Wang J; Zhu J; Zeng F; Yao XQ; Gao CY; Xu ZQ; Zhou XF; Wang YJ
    Neurobiol Dis; 2019 Dec; 132():104567. PubMed ID: 31394202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rifampicin is a candidate preventive medicine against amyloid-β and tau oligomers.
    Umeda T; Ono K; Sakai A; Yamashita M; Mizuguchi M; Klein WL; Yamada M; Mori H; Tomiyama T
    Brain; 2016 May; 139(Pt 5):1568-86. PubMed ID: 27020329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles.
    Caccamo A; Oddo S; Tran LX; LaFerla FM
    Am J Pathol; 2007 May; 170(5):1669-75. PubMed ID: 17456772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isorhynchophylline ameliorates cognitive impairment via modulating amyloid pathology, tau hyperphosphorylation and neuroinflammation: Studies in a transgenic mouse model of Alzheimer's disease.
    Li HQ; Ip SP; Yuan QJ; Zheng GQ; Tsim KKW; Dong TTX; Lin G; Han Y; Liu Y; Xian YF; Lin ZX
    Brain Behav Immun; 2019 Nov; 82():264-278. PubMed ID: 31476414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lithium down-regulates tau in cultured cortical neurons: a possible mechanism of neuroprotection.
    Rametti A; Esclaire F; Yardin C; Cogné N; Terro F
    Neurosci Lett; 2008 Mar; 434(1):93-8. PubMed ID: 18289787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Propentofylline attenuates tau hyperphosphorylation in Alzheimer's Swedish mutant model Tg2576.
    Chauhan NB; Siegel GJ; Feinstein DL
    Neuropharmacology; 2005 Jan; 48(1):93-104. PubMed ID: 15617731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amyloid-β pathology is attenuated by tauroursodeoxycholic acid treatment in APP/PS1 mice after disease onset.
    Dionísio PA; Amaral JD; Ribeiro MF; Lo AC; D'Hooge R; Rodrigues CM
    Neurobiol Aging; 2015 Jan; 36(1):228-40. PubMed ID: 25443293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mNos2 deletion and human NOS2 replacement in Alzheimer disease models.
    Colton CA; Wilson JG; Everhart A; Wilcock DM; Puoliväli J; Heikkinen T; Oksman J; Jääskeläinen O; Lehtimäki K; Laitinen T; Vartiainen N; Vitek MP
    J Neuropathol Exp Neurol; 2014 Aug; 73(8):752-69. PubMed ID: 25003233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atorvastatin ameliorates cognitive impairment, Aβ1-42 production and Tau hyperphosphorylation in APP/PS1 transgenic mice.
    Zhou D; Liu H; Li C; Wang F; Shi Y; Liu L; Zhao X; Liu A; Zhang J; Wang C; Chen Z
    Metab Brain Dis; 2016 Jun; 31(3):693-703. PubMed ID: 26883430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interplay between cyclin-dependent kinase 5 and glycogen synthase kinase 3 beta mediated by neuregulin signaling leads to differential effects on tau phosphorylation and amyloid precursor protein processing.
    Wen Y; Planel E; Herman M; Figueroa HY; Wang L; Liu L; Lau LF; Yu WH; Duff KE
    J Neurosci; 2008 Mar; 28(10):2624-32. PubMed ID: 18322105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.